The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2024

Filed:

Nov. 11, 2020
Applicant:

City of Hope, Duarte, CA (US);

Inventors:

Felix Wussow, Glendora, CA (US);

Don J. Diamond, Glendora, CA (US);

Heidi Contreras, Pasadena, CA (US);

Assignee:

CITY OF HOPE, Duarte, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 39/245 (2013.01); C07K 14/005 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/70 (2013.01); C07K 2319/40 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24143 (2013.01); C12N 2800/22 (2013.01);
Abstract

A vaccine composition comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus comprising IE1, IE2 and pp65 or antigenic fragments thereof, which is genetically stable after at least 10 passages. A method of improving the stability of such rMVA upon passage by including one or more of the modifications: (1) inserting one or more nucleic acid sequences encoding the CMV antigens or antigenic fragments thereof into one or more insertion sites including but not limited to 044L/045L, IGR3, G1L/18R, and Del3 but not including Del2; (2) codon optimizing the nucleic acid sequences encoding the CMV antigens by removing consecutive cytosines or guanines; and (3) introducing one or more mutations in the amino acid sequences of the CMV antigens.


Find Patent Forward Citations

Loading…